Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$18.43

0.32 (1.77%)

, AVXS

AveXis

$47.51

2.35 (5.20%)

10:09
10/10/16
10/10
10:09
10/10/16
10:09

AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray

Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.

BOLD

Audentes Therapeutics

$18.43

0.32 (1.77%)

AVXS

AveXis

$47.51

2.35 (5.20%)

  • 10

    Oct

  • 06

    Nov

BOLD Audentes Therapeutics
$18.43

0.32 (1.77%)

08/15/16
PIPR
08/15/16
INITIATION
Target $24
PIPR
Overweight
Audentes Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer started Audentes Therapeutics with an Overweight rating and $24 price target. The analyst views the company as well-positioned in the "rapidly evolving gene therapy landscape."
08/15/16
COWN
08/15/16
INITIATION
COWN
Outperform
Audentes Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral started Audentes Therapeutics with an Outperform rating.
08/15/16
WEDB
08/15/16
INITIATION
Target $20
WEDB
Outperform
Audentes Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated Audentes Therapeutics with an Outperform and $20 price target saying its a compelling opportunity in AAV gene therapy of rare diseases.
AVXS AveXis
$47.51

2.35 (5.20%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

HLX

Helix Energy

$7.41

-0.32 (-4.14%)

19:24
02/20/17
02/20
19:24
02/20/17
19:24
Earnings
Helix Energy reports Q4 EPS with items (46c), may not compare to consensus (6c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CSII

Cardiovascular Systems

$29.19

0.76 (2.67%)

19:21
02/20/17
02/20
19:21
02/20/17
19:21
Hot Stocks
Cardiovascular Systems reports one-year data from COAST study »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMT

America's Car-Mart

$38.85

-1.15 (-2.88%)

19:17
02/20/17
02/20
19:17
02/20/17
19:17
Earnings
America's Car-Mart reports Q3 EPS 35c, may not compare to consensus 64c »

Reports Q3 revenue $139M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:12
02/20/17
02/20
19:12
02/20/17
19:12
Earnings
Rogers Corporation sees Q1 adjusted EPS $1.09-$1.19, consensus 99c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:11
02/20/17
02/20
19:11
02/20/17
19:11
Earnings
Rogers Corporation reports Q4 EPS 94c, consensus 82c »

Reports Q4 revenue $173M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

, FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

19:04
02/20/17
02/20
19:04
02/20/17
19:04
Hot Stocks
Hancock Holding says gets approval to close First NBC Bank transaction »

Hancock Holding (HBHC)…

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$119.95

0.77 (0.65%)

19:03
02/20/17
02/20
19:03
02/20/17
19:03
Earnings
Nordson sees Q2 EPS $1.21-$1.33, consensus $1.22 »

Sees Q2 revenue up 3%-7%.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:01
02/20/17
02/20
19:01
02/20/17
19:01
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson says order rates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:00
02/20/17
02/20
19:00
02/20/17
19:00
Earnings
Nordson reports Q1 EPS 86c, consensus 82c »

Reports Q1 revenue $407M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

18:57
02/20/17
02/20
18:57
02/20/17
18:57
Hot Stocks
Nordson to acquire Vention AT for $705M »

Nordson announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:55
02/20/17
02/20
18:55
02/20/17
18:55
Earnings
Community Health sees FY17 cont ops EPS 30c-$1.10 »

EPS consensus 61c. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:51
02/20/17
02/20
18:51
02/20/17
18:51
Earnings
Community Health reports Q4 adjusted EPS 46c, may not compare to consensus 13c »

Reports Q4 net operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

HSIC

Henry Schein

$168.11

0.86 (0.51%)

18:47
02/20/17
02/20
18:47
02/20/17
18:47
Hot Stocks
Henry Schein to acquire Southern Anesthesia + Surgical »

Henry Schein announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 24

    Feb

UIHC

United Insurance

$15.95

0.01 (0.06%)

18:45
02/20/17
02/20
18:45
02/20/17
18:45
Earnings
United Insurance reports Q4 EPS (49c), consensus (39c) »

Reports Q4 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:40
02/20/17
02/20
18:40
02/20/17
18:40
Earnings
Breaking Earnings news story on Vipshop »

Vipshop sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:39
02/20/17
02/20
18:39
02/20/17
18:39
Earnings
Vipshop reports Q4 adjusted income per ADS 23c, consensus 21c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

, BK

BNY Mellon

$47.14

0.07 (0.15%)

18:36
02/20/17
02/20
18:36
02/20/17
18:36
Hot Stocks
Wells Fargo names two new independent directors »

The board of Wells Fargo…

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

BK

BNY Mellon

$47.14

0.07 (0.15%)

SPLS

Staples

$9.31

0.04 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

BIOA

BioAmber

$3.66

-0.07 (-1.88%)

18:33
02/20/17
02/20
18:33
02/20/17
18:33
Hot Stocks
BioAmber says CEO Huc resigns, COO Orecchioni appointed president »

BioAmber announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBB

Cincinnati Bell

$19.85

-0.65 (-3.17%)

18:31
02/20/17
02/20
18:31
02/20/17
18:31
Hot Stocks
Cincinnati Bell subsidiary acquires SunTel Services »

CBTS, a wholly-owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VZ

Verizon

$49.19

0.73 (1.51%)

, AAPL

Apple

$135.72

0.375 (0.28%)

18:23
02/20/17
02/20
18:23
02/20/17
18:23
Hot Stocks
Verizon appoints Apple's Andrew McKechnie as creative chief of in-house agency »

Verizon (VZ) announced…

VZ

Verizon

$49.19

0.73 (1.51%)

AAPL

Apple

$135.72

0.375 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 13

    Mar

NEE

NextEra Energy

$126.86

0.67 (0.53%)

18:19
02/20/17
02/20
18:19
02/20/17
18:19
Hot Stocks
NextEra Energy subsidiary says expands solar energy projects »

NextEra Energy subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SNX

SYNNEX

$118.37

-0.23 (-0.19%)

18:14
02/20/17
02/20
18:14
02/20/17
18:14
Hot Stocks
Raritan announces distribution agreement with SYNNEX »

Raritan, a provider of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$14.91

-0.16 (-1.06%)

18:06
02/20/17
02/20
18:06
02/20/17
18:06
Hot Stocks
Freeport McMoRan says fails to reach deal with Indonesia, sees Q1 sales impact »

Freeport McMoRan issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WEN

Wendy's

$14.13

0.44 (3.21%)

18:01
02/20/17
02/20
18:01
02/20/17
18:01
Hot Stocks
Delight Restaurant Group acquires 30 Wendy's restaurants »

Delight Restaurant Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CMG

Chipotle

$427.61

2.85 (0.67%)

17:59
02/20/17
02/20
17:59
02/20/17
17:59
Hot Stocks
Chipotle says 'Smarter Pickup Times' technology rolled out across U.S. »

Chipotle announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.